Thylacine Biotherapeutics Inc. has entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform invented and refined at Columbia.
Hearing loss related to aging is mostly predicted by the degree of loss of outer hair cells. Investigators from Acousia Therapeutics GmbH have tested the novel Kv7.4 channel activator ACOU-082 in mice.
Ryne Biotechnology Inc. has been awarded a US$4 million Clinical Stage Research Program (CLIN1) grant by the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001 through IND submission in the next 12 months.
Scientists have identified proteins that changed in response to exercise specifically in trial participants whose blood sugar control improved after taking up an exercise regimen. Based on serum protein analysis, the investigators also developed a machine-learning algorithm that could predict whether an individual’s metabolic sensitivity would be improved by exercise.
Heart failure is a common condition: according to a new study in 11 high-income countries, an estimated 1-2% of the population has heart failure. One feature of late-stage heart failure is nicotine adenine dinucleotide (NAD+), which leaves heart muscle cells unable to generate sufficient ATP to meet their energy needs. Now, investigators at The Hospital for Sick Children and the University of Toronto have shown that this metabolic dysfunction is present early in heart failure, and precedes any sign of clinical dysfunction in the heart.
Lateral Pharma Pty. Ltd. has discovered peptides targeting LanC-like (LANCL) proteins reported to be useful for the treatment of diabetes, infections, inflammation, obesity, pain, metabolic, muscle and neurological disorders, among others.
Shanghai Allist Pharmaceuticals Co. Ltd. has discovered pyridopyrimidines acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has divulged amide compounds acting as epidermal growth factor receptor (EGFR) mutant inhibitors reported to be useful for the treatment of cancer.
RSS
